Genedrive PLC Director/PDMR Shareholding (9066F)

TIDMGDR

RNS Number : 9066F

Genedrive PLC

18 July 2019

Notification and public disclosure of transactions by persons discharging

managerial responsibilities and persons closely associated with them

genedrive plc (LSE: GDR) ("genedrive" or the "Company"), the near patient molecular diagnostics company, announces that Dr Ian Gilham, Non-Executive Chairman, acquired 51,250 ordinary shares of 1.5p each ("Ordinary Shares") in the Company at an average price of 19p per share.

Following these purchases, Dr Gilham is interested in 317,674 Ordinary Shares, 0.93% of the issued share capital of the Company.

The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

 
            1.   Details of the person discharging managerial responsibilities 
                  / person closely associated 
      a.         Name                                       Ian Gilham 
                ------------------------------  ---------------------------------- 
            2.   Reason for the notification 
                ------------------------------------------------------------------ 
            a.   Position/status                 Non-Executive Chairman 
                ------------------------------  ---------------------------------- 
            a.   Initial notification            Initial notification 
                  /Amendment 
                ------------------------------  ---------------------------------- 
  3.             Details of the issuer, emission allowance market participant, 
                  auction platform, auctioneer or auction monitor 
                ------------------------------------------------------------------ 
            a.   Name                            genedrive plc 
                ------------------------------  ---------------------------------- 
            b.   LEI                             213800ZYODIRZ87Y4K14 
                ------------------------------  ---------------------------------- 
            4.   Details of the transaction(s): section to be repeated for 
                  (i) each type of instrument; (ii) each type of transaction; 
                  (iii) each date; and (iv) each place where transactions 
                  have been conducted 
                ------------------------------------------------------------------ 
            a.   Description of                  Ordinary shares of 1.5 pence each 
                  the 
                  Financial instrument, 
                  type 
                  of instrument 
                  Identification 
                  code 
                ------------------------------  ---------------------------------- 
            b.   Nature of the                              Purchase 
                  transaction 
                ------------------------------  ---------------------------------- 
            c.   Price(s) and                      Price(s)   Volume(s) 
                  volume(s)                              19p      51,250 
                                                              ---------- 
                ------------------------------  ---------------------------------- 
            d.        Aggregated information 
                        *    Aggregated volume     N/A 
 
 
                        *    Price 
                ------------------------------  ---------------------------------- 
            e.   Date of the transaction         2019-07-17; UTC time 
                ------------------------------  ---------------------------------- 
            f.   Place of the                    London Stock Exchange, AIM 
                  transaction 
                ------------------------------  ---------------------------------- 
 

For further details please contact:

 
 genedrive plc                                     [phone] 
 David Budd: CEO 
 Matthew Fowler: CFO 
 Peel Hunt LLP                                     [phone] 
 James Steel 
 Oliver Jackson 
 
              Stanford Capital Partners Limited                                  [phone] 
 
              Patrick Claridge / John Howes 
 
 Walbrook PR Ltd (Media Relations 
  & Investor Relations)                              [phone] or [e-mail] 
                                                   [phone] / +44 (0)7876 
 Paul McManus / Anna Dunphy                         741 001 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHEAEXXFSSNEAF

(END) Dow Jones Newswires

July 18, 2019 02:00 ET (06:00 GMT)